TeleNeuMu

Instituto Pedro Molina – IPM has been developing the TeleNeuMu app since 2021, which brings important innovation in the contact between patients and families, doctors and health professionals. Connectivity is the main mission – to provide, in a simple and objective way, the discovery of how many we are, where we are, who we are. Direct connection of the patient with doctors and health professionals.
Benefits of the TeleNeuMu Application:
-Connect patients, doctors and health professionals.
- Enable the patient to schedule an in-person consultation or telemedicine.
-Has the “Patient Diary” so that it can be filled in and can be used in medical consultations.
-Place for the patient to attach exams and make it available to the doctor.
-Useful information about neuromuscular diseases shared by healthcare professionals.
-Optional access to services provided and managed by partners.
-The app's qualified database will enable scientific studies to be carried out.

We currently have two partnerships:
•SIDNM - Neuromuscular Diseases Research Sector - Created in 1976 by the Department of Neurology and Neurosurgery of Escola Paulista de Medicina with the aim of contributing to: Assistance for patients (consultation, multidisciplinary guidance, integrative care, exams), Education (courses) , Research (Epidemiology, quality of life, new therapies).
The partnership with IPM seeks to:
-Support in the property where patient care takes place.
-Donation of basic food baskets for patients and family members treated at SIDNM.
-Make TeleNeuMu available, connecting patients and doctors for better care.
-Expansion of application use to other specialties in partnership with SPDM (Paulista Association for the Development of Medicine) and Unifesp (Federal University of São Paulo).
•ABRAFEU - Brazilian Facio-Scapulo-Humeral Association - Abrafeu aims to provide assistance to people with a genetic condition called Facio-Scapulo-Humeral Muscular Dystrophy and their families.
The partnership with IPM seeks to:
-Through TeleNeuMu, connect the patient with the DNA testing project according to norms and rules established and managed by Abrafeu itself, which will have a database of patients to apply and accredit Brazil to bring a “clinical trial” ” (clinical trial) for future genetic treatment